Deals
After debuting on the public markets with $256.3 million and raking in an additional $472 million, Veradermics has emerged as one of biotech’s biggest post-IPO standouts. CEO Reid Waldman credits the weight loss craze for establishing consumer-driven channels.
FEATURED STORIES
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
While merger and acquisition activity has been robust of late, frequent changes in guidance and leadership at the regulator add risk to any transaction.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Adding to its list of achievements, on Tuesday the Swiss biotech announced it is acquiring Comet Therapeutics.
The hot days of summer are nearing a close, but these life science companies aren’t cooling off their fundraising efforts. Here’s a brief overview of who’s heating up their coffers this week.
The SPAC craze continues as San Diego-based Revelation Biosciences announced its merger with Petra Acquisition that will result in the company’s listing on the Nasdaq exchange.
The combined company out of the Humacyte SPAC will be called Humacyte and is expected to trade shares of common stock and warrants on the Nasdaq Global Select Market.
Tyra Biosciences aspires to raise a $100 million IPO, according to its S-1 form filed with the U.S. Securities and Exchange commission late last week.
Under the terms of the deal, Pfizer is picking up all outstanding shares of Trillium that it doesn’t already own for $18.50 per share in cash.
Google’s Verily snapped up N.C.-based SignalPath and its clinical trial management system that is expected to support its own clinical trial and evidence-based platform known as Baseline.
The Canadian biotech announced the acquisition of two new pipeline assets that align with its focus on autoimmune and kidney-related disease.
Amidst a chorus of pushback from scientific and health organizations, Philip Morris International’s $1.4 billion offer now has the backing of Vectura Group’s board.